Can Fite Biopharma (CANF) Stock Price, Quote, News & History | Benzinga

SPY767.49+0.56%QQQ719.90+1.42%BTC/USD—DIA519.30+0.04%GLD379.54−0.65%TLT79.47−0.72%

Can Fite Biopharma Ltd (CANF) Stock Price, Quote, News & History

CANFAMEX

Trade with Public

Trade with Public

$1.86

0.105.68%

Last update: Oct 19, 12:24 PM

$1.88

0.126.82%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Compare Stock Report

Key Statistics

Open

$1.82

Close

-

Volume / Avg.

8.68K / 357.38K

Day Range

$1.80 - $1.92

52 Wk Range

1.85 - 1.18K

Market Cap

$3.99M

P/E Ratio

-

Dividend Yield

-

Exchange

AMEX

RSI

32

Short Interest

2.61%

Days to Cover

1.18

Recent Can Fite Biopharma Ltd News

Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study

Can-Fite BioPharma reports longer survival in its Phase 3 liver cancer trial and raises $4 million through a warrant exercise.

Vandana Singh

Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients

Can-Fite's Phase 2a Namodenoson study met its safety endpoint and showed durable survival, supporting a Phase 2b chemotherapy trial.

Vandana Singh

Can-Fite Stock Jumps After Japan Patent Boosts Obesity Drug Case

Can-Fite stock rises after Japan patent allowance strengthens Namodenoson’s obesity and metabolic disease opportunity.

Akanksha Bakshi

Nasdaq Surges Over 1%; ISM Services PMI Tops Views

U.S. stocks up on Wednesday with NASDAQ gaining 0.85%. ISM services PMI rose to 56.1. VCI Global Ltd, Latham Group Inc, and Can Fite Biopharma surge.

Avi Kapoor

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

Can-Fite stock jumps after Namodenoson improves survival in pancreatic cancer Phase 2a study with a strong safety profile.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-9.51M

Investing Cash Flow (TTM)

-4.00M

Financing Cash Flow (TTM)

10.04M

Free Cash Flow (TTM)

-9.51M

Capital Expenditure (TTM)

-2.00K

Net Change in Cash (TTM)

-3.47M

Analyst Trends and Forecast

2

May

1

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$2.80M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

6.77

PB Ratio (TTM)

0.78

Earnings Yield % (TTM)

-263.98%

Earnings Yield % (FWD)

-51.70%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.27

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$2.99M

Debt to Equity

0.01

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-